Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML

Author:

Chaturvedi Anuhar1,Araujo Cruz Michelle Maria1,Jyotsana Nidhi1,Sharma Amit1,Yun Haiyang1,Görlich Kerstin1,Wichmann Martin1,Schwarzer Adrian2,Preller Matthias3,Thol Felicitas1,Meyer Johann2,Haemmerle Reinhard2,Struys Eduard A.4,Jansen Erwin E.4,Modlich Ute2,Li Zhixiong2,Sly Laura M.5,Geffers Robert6,Lindner Robert7,Manstein Dietmar J.3,Lehmann Ulrich8,Krauter Jürgen1,Ganser Arnold1,Heuser Michael1

Affiliation:

1. Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation,

2. Institute of Experimental Hematology, and

3. Institute for Biophysical Chemistry and Research Division for Structural Analysis, Hannover Medical School, Hannover, Germany;

4. Department of Clinical Chemistry, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands;

5. Child and Family Research Institute, University of British Columbia, Vancouver, BC, Canada;

6. Department of Cell Biology and Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany; and

7. Institute of Cell Biology, and

8. Institute of Pathology, Hannover Medical School, Hannover, Germany

Abstract

Key Points IDH1 promotes leukemogenesis in vivo in cooperation with HoxA9. Pharmacologic inhibition of mutant IDH1 efficiently inhibits AML cells of IDH1-mutated patients but not of normal CD34+ bone marrow cells.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 180 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3